VXLLF (Vaxil Bio) Ending Cash Position: $0.38 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VXLLF Vaxil Bio Ltd VXLLF
38 GF Score
Price $0.03
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio Ending Cash Position?

Vaxil Bio VXLLF 38 Ending Cash Position is $0.38 Mil as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Vaxil Bio's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.38 Mil.

Vaxil Bio's quarterly Ending Cash Position increased from Sep. 2025 ($0.32 Mil) to Dec. 2025 ($0.49 Mil) but then declined from Dec. 2025 ($0.49 Mil) to Mar. 2026 ($0.38 Mil).

Vaxil Bio's annual Ending Cash Position declined from Dec. 2023 ($0.70 Mil) to Dec. 2024 ($0.31 Mil) but then increased from Dec. 2024 ($0.31 Mil) to Dec. 2025 ($0.49 Mil).

Vaxil Bio Ending Cash Position Related Terms

Vaxil Bio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio Ending Cash Position Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 1.11 0.70 0.31 0.49

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.25 0.32 0.49 0.38
VXLLF
38GF Score
Vaxil Bio Ltd VXLLF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vaxil Bio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.316+0.17
=0.49

Vaxil Bio's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.489+-0.105
=0.38

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.38 Mil mean?
Vaxil Bio (VXLLF) has a Ending Cash Position of $0.38 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vaxil Bio and its competitors.
Is Vaxil Bio's Ending Cash Position too high?
Vaxil Bio's current Ending Cash Position is $0.38 Mil. Overall, Vaxil Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's Ending Cash Position compare to VRTX and REGN?
Vaxil Bio's Ending Cash Position of $0.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vaxil Bio and its competitors. Vaxil Bio's current Ending Cash Position is $0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current Ending Cash Position of $0.38 Mil. The current Ending Cash Position is $0.38 Mil. Vaxil Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current Ending Cash Position is $0.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
38GF Score

Get the complete analysis for VXLLF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price